These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 38695305)

  • 1. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities.
    Wang MD; Xu XJ; Wang KC; Diao YK; Xu JH; Gu LH; Yao LQ; Li C; Lv GY; Yang T
    Cancer Sci; 2024 Jul; 115(7):2159-2169. PubMed ID: 38695305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma.
    Takamoto T; Maruki Y; Kondo S
    Expert Opin Pharmacother; 2023; 24(14):1567-1575. PubMed ID: 37357809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
    Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
    Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.
    Bai J; Huang M; Song B; Luo W; Ding R
    Technol Cancer Res Treat; 2023; 22():15330338231159718. PubMed ID: 36855803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
    Akateh C; Black SM; Conteh L; Miller ED; Noonan A; Elliott E; Pawlik TM; Tsung A; Cloyd JM
    World J Gastroenterol; 2019 Jul; 25(28):3704-3721. PubMed ID: 31391767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review.
    Zhang Z; Zhang E
    Front Immunol; 2023; 14():1073531. PubMed ID: 37180144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
    Urquijo-Ponce JJ; Alventosa-Mateu C; Latorre-Sánchez M; Castelló-Miralles I; Diago M
    World J Gastroenterol; 2024 May; 30(19):2512-2522. PubMed ID: 38817666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview.
    Sun HC; Zhu XD
    Front Oncol; 2021; 11():772195. PubMed ID: 34869008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
    Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.
    Zhou H; Song T
    Biosci Trends; 2021 Jul; 15(3):155-160. PubMed ID: 34039818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches.
    Lindemann J; Yu J; Doyle MBM
    Surg Oncol Clin N Am; 2024 Jan; 33(1):143-158. PubMed ID: 37945140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?
    Jiang C; Sun XD; Qiu W; Chen YG; Sun DW; Lv GY
    Hepatobiliary Pancreat Dis Int; 2023 Feb; 22(1):7-13. PubMed ID: 36825482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
    Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
    Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities.
    da Fonseca LG; Araujo RLC
    World J Gastroenterol; 2022 Jul; 28(28):3573-3585. PubMed ID: 36161045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
    Colombo M; Raoul JL; Lencioni R; Galle PR; Zucman-Rossi J; Bañares R; Seehofer D; Neuhaus P; Johnson P
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):639-51. PubMed ID: 23628963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.
    Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ
    Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
    Yoon HI; Seong J
    Oncology; 2014; 87 Suppl 1():90-8. PubMed ID: 25427739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Local and Systemic Therapies for Hepatocellular Cancer.
    Mokdad AA; Singal AG; Yopp AC
    Curr Oncol Rep; 2016 Feb; 18(2):9. PubMed ID: 26769114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hepatocellular carcinoma.
    Said A; Wells J
    Minerva Med; 2009 Feb; 100(1):51-68. PubMed ID: 19277004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downstaging strategies for unresectable hepatocellular carcinoma.
    Karachaliou GS; Dimitrokallis N; Moris DP
    World J Gastroenterol; 2024 May; 30(20):2731-2733. PubMed ID: 38855157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.